SCHEMBL4185752

SCHEMBL4185752

O=C(Cc1cccc(C(F)(F)F)c1)c1c(O)c2cccnc2n(-c2ccccc2)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.47
POLB P06746 1/20 0.47
CXCR3 P49682 1/20 0.43
PPARG P37231 1/20 0.43
PDE1A P54750 1/20 0.43
PDE1B Q01064 1/20 0.43
PDE4A P27815 2/20 0.42
FEN1 P39748 2/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
REN P00797 1/20 0.40
LMNA P02545 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
CCR1 P32246 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4183574 0.95 TP53 (0.44) TP53POLBCXCR3PPARGFEN1
SCHEMBL4187658 0.94 POLB (0.47) TP53POLBPPARGPDE1APDE1B
SCHEMBL4187633 0.89 PPARG (0.41) TP53POLBCXCR3PPARGFEN1
SCHEMBL4183644 0.89 TP53 (0.43) TP53POLBCXCR3PPARGMAPT
SCHEMBL4195071 0.87 CNR2 (0.44) TP53POLBCXCR3PPARGMAPT
SCHEMBL2409456 0.87 PDE1A (0.51) PDE1APDE1BPDE4AFEN1MAPT
SCHEMBL4190734 0.87 PPARG (0.41) TP53POLBCXCR3PPARGFEN1
SCHEMBL13685422 0.86 TP53 (0.40) TP53POLBPDE1APDE1BPDE4A
SCHEMBL13685423 0.85 PDE4A (0.42) TP53POLBPDE1APDE1BPDE4A
SCHEMBL4187214 0.84 POLB (0.45) TP53POLBPPARGMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A TP53 4856/4885POLB 1630/4885CXCR3 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.